Synonym
Naltalimide; TRK-130; TRK130; TRK 130
IUPAC/Chemical Name
N-[(5R, 6R, 14S)-17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxymorphinan-6-yl] phthalimide
InChi Key
DHAITNWJDOSRBU-IBHWKQIPSA-N
InChi Code
InChI=1S/C28H28N2O5/c31-20-8-7-16-13-21-28(34)10-9-19(30-25(32)17-3-1-2-4-18(17)26(30)33)24-27(28,22(16)23(20)35-24)11-12-29(21)14-15-5-6-15/h1-4,7-8,15,19,21,24,31,34H,5-6,9-14H2/t19-,21-,24+,27+,28-/m1/s1
SMILES Code
O=C(N1[C@H]2[C@@]3([H])[C@]45C6=C(O3)C(O)=CC=C6C[C@@H](N(CC7CC7)CC5)[C@]4(O)CC2)C8=CC=CC=C8C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
472.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fujimura M, Izumimoto N, Momen S, Yoshikawa S, Kobayashi R, Kanie S, Hirakata M, Komagata T, Okanishi S, Hashimoto T, Yoshimura N, Kawai K. Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Pharmacol Exp Ther. 2014 Sep;350(3):543-51. doi: 10.1124/jpet.114.214031. Epub 2014 Jun 13. PubMed PMID: 24928951.
2: Atala A. Re: Characteristics of TRK-130 (naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Urol. 2015 Mar;193(3):1060. doi: 10.1016/j.juro.2014.12.029. Epub 2014 Dec 18. PubMed PMID: 25765428.
3: Wein AJ. Re: Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder. J Urol. 2016 Jan;195(1):223. doi: 10.1016/j.juro.2015.10.078. Epub 2015 Nov 21. PubMed PMID: 26699998.
4: Fujimura M, Izumimoto N, Kanie S, Kobayashi R, Yoshikawa S, Momen S, Hirakata M, Komagata T, Okanishi S, Iwata M, Hashimoto T, Doi T, Yoshimura N, Kawai K. Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex. Int Urol Nephrol. 2017 Apr;49(4):587-595. doi: 10.1007/s11255-017-1509-y. Epub 2017 Jan 16. PubMed PMID: 28093646.